The U.S. Food and Drug Administration (FDA) has approved Johnson & Johnson's nasal spray, Spravato (esketamine), as the first ...
The U.S. Food and Drug Administration has approved a nasal spray to treat depression—the first-ever stand-alone medication for patients with severe depression. Johnson & Johnson said patients who use ...
J&J on Tuesday said the green light makes Spravato the first and only monotherapy for adults with major depressive disorder who have had an inadequate response to at least two oral antidepressants.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback